IMU Picks up the Pace in Cancer Drug Treatment Development

Aug 9, 2017

It is difficult to understate the possible impact of the immuno-oncology therapies that the $33 million-capped Imugene (ASX: IMU) is currently developing. These therapies, if proven safe and successful, could have an undeniable real world positive effect for cancer patients.

Read Article

CPH Signs Exclusive Cannapharm deal: On Track for 2017 Product Release

Jun 14, 2017

News of $100 million IPOs, alongside an avalanche of parallel legislative changes around the world, builds a strong case for the burgeoning medicinal marijuana industry. With so many medicinal cannabis stocks fighting for market share and threatening to steal the limelight, a company such as Creso Pharma Ltd (ASX: CPH) needs to do all it can to stay current and competitive.

Read Article

CPH Deliver Australia’s First Medicinal Cannabis Shipment Under New Legislation

May 2, 2017

Creso Pharma (ASX: CPH) has made a shipment of medicinal cannabis into Australia – the first import into the country under new government legislation. Under an agreement between CPH and its Australian partner, Health House International Pty Ltd, the pair will distribute a range of cannabis oil products across Australian pharmacies, in compliance with Federal and State legislation.

Read Article
Be alerted as soon as an article is released - Join our mailing list (FREE)
  • close

Are you a sophisticated investor?